XORTX Therapeutics Inc XRTX

Primary Symbol: V.XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > LOOKS

<< Previous

Bullboard Posts

Next >>

Comment by SpaceLabson Jan 04, 2022 8:24pm

96 Views

Post# 34283698

RE:RE:LOOKS

diamondlessnono wrote: 2022, here we go up.

My friends are back from the Brooms, good try. it pulled back on small# of crumb ryes.

Well,, AB has his Gill Net in Red bow and takes em all before any shrs float past his Gnet !

Omicron is surging all over the planet, more contageous than Delta.
Lets hope Dr. Chivago XRX gets fast tracked his Loonie by FDA early in 2022 to give it a lift-off.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market